View clinical trials related to Influenza.Filter by:
This clinical study will assess the safety, tolerability and immunogenicity of VAL-506440 in healthy adult subjects.
This study will evaluate in detail the way that the immune system responds to three different kinds of flu shots that are licensed in the United States.
The objective of this study is to evaluate the safety and efficacy of concurrent administration of influenza vaccine in patients receiving anti-PD1 immunotherapy (nivolumab or pembrolizumab). This will be a prospective observational study, aiming to assess patient tolerance of treatment, adverse events (incidence, grade, need for hospitalization), incidence of influenza infections, and seroconversion rates.
This is a Phase II randomized, double-blind, placebo-controlled trial in 240 males and non-pregnant females, 18 to 45 years old, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of two priming doses of M-001 followed by boosting with two doses of MF59-adjuvanted or non-adjuvanted monovalent influenza A/H7N9 IIV. The monovalent influenza A/H7N9 IIV was derived from the HA of the influenza A/Shanghai/2/2013 (H7N9) virus. Primary objectives: To assess the safety and reactogenicity of M-001 vaccine following receipt of two doses; To assess the safety and reactogenicity of a monovalent inactivated influenza A/H7N9 vaccine (A/H7N9 IIV; two doses) administered with or without MF59 adjuvant following immunization with two doses of M-001 vaccine or placebo, and to assess the serum hemagglutination inhibition (HAI) antibody responses to the A/H7N9 IIV virus after receipt of the first and second dose of MF59 adjuvanted or non-adjuvanted A/H7N9 IIV when administered to adults following receipt of placebo or two doses of M-001 vaccine.
The purpose of this study is provide a better understanding of the adaptive immune response to the licensed flu vaccines. The investigators hope the information learned from this study will help identify and describe important factors of influenza immunity especially of or specific proteins associated with the T-cell immune response.
The purpose of the study is to get a better understanding of the natural and adaptive immune response to the flu virus and to compare the immune cell responses to FDA-licensed flu vaccines in nasal mucosal cells and in blood.
The investigators collected blood and lymphoid tissues routinely discarded during surgery from adults after a routine seasonal influenza vaccination to determine how immune memory develops at the actual site of infection, and how immunization may alter this process.
The purpose of the study is to investigate and compare the human immune response in epithelial cells of the nasopharyngeal mucosa and in blood to live, attenuated influenza vaccine (LAIV) in adults and in children.
This study will examine the immune responses to the seasonal influenza vaccine in single cells of the nasal passages when compared with cells in circulating blood.
This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.